imatinib mesylate has been researched along with Atrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, O; Amemiya, S; Baba, A; Fujita, N; Gonoi, W; Hagiwara, A; Kawahara, T; Kurokawa, M; Kurokawa, R; Nakai, Y; Ota, Y; Yamaguchi, H | 1 |
| Li, KD; Salama, ME | 1 |
1 review(s) available for imatinib mesylate and Atrophy
| Article | Year |
|---|---|
Therapy Effect: Impact on Bone Marrow Morphology.
Topics: Antineoplastic Agents; Atrophy; Bone Marrow; Cytokines; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myeloablative Agonists; Necrosis; Rituximab; Thalidomide | 2016 |
1 other study(ies) available for imatinib mesylate and Atrophy
| Article | Year |
|---|---|
Imatinib-induced pancreatic hypertrophy in patients with gastrointestinal stromal tumor: Association with overall survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertrophy; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Pancreas; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2021 |